EFPIA Highlights Europe ‘Lessons’ As Japan Ponders Policies
This article was originally published in PharmAsia News
Executive Summary
EFPIA remains cautious over moves in Japan towards a formal health technology assessment system and possible changes to the reimbursement pricing system, calling again for the maintenance of an environment conducive to pharma innovation and pointing to lessons from its experience in Europe.
You may also be interested in...
Japan Firms Up Cost-Effectiveness Plans As Industry Concerns Linger
Japan firms up proposals for expanded cost-effectiveness assessment scheme for selected drugs and devices after a policy committee outlines plans that could see associated price adjustments for reviewed products.
EFPIA Urges Japan To Consider New Funding Models
Amid intensifying official scrutiny of rising drug costs, the European industry federation EFPIA would like Japan to focus more on the measuring the actual benefits and health outcomes of new therapies, helped by new approaches and technology.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.